(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.06%) $78.11
(5.70%) $2.15
(0.03%) $2 310.20
(-0.15%) $26.79
(0.15%) $964.05
(-0.36%) $0.929
(-1.14%) $10.87
(-0.14%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...
Stats | |
---|---|
今日成交量 | 16 865.00 |
平均成交量 | 20 800.00 |
市值 | 20.39M |
EPS | $0 ( 2024-02-08 ) |
下一个收益日期 | ( $-1.520 ) 2024-05-09 |
Last Dividend | $1.750 ( 2023-11-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 1.030 |
ATR14 | $0.0250 (0.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-18 | Flynn James P | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Flynn James P | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.96 |
Last 96 transactions |
Buy: 9 932 993 | Sell: 849 643 |
MEI Pharma Inc 财务报表
Annual | 2023 |
营收: | $48.82M |
毛利润: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2023 |
营收: | $48.82M |
毛利润: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2022 |
营收: | $40.70M |
毛利润: | $39.46M (96.97 %) |
EPS: | $-8.80 |
FY | 2021 |
营收: | $25.54M |
毛利润: | $24.13M (94.49 %) |
EPS: | $-0.450 |
Financial Reports:
No articles found.
MEI Pharma Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.750 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.750 | 2023-11-16 |
Last Dividend | $1.750 | 2023-11-16 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.750 | -- |
Avg. Dividend % Per Year | 11.67% | -- |
Score | 4.75 | -- |
Div. Sustainability Score | 5.51 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 2.48 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.750 | 35.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.286 | 1.500 | 4.27 | 6.41 | [0 - 0.5] |
returnOnAssetsTTM | 0.265 | 1.200 | 1.173 | 1.408 | [0 - 0.3] |
returnOnEquityTTM | 0.416 | 1.500 | 6.49 | 9.73 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.23 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.40 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.644 | 1.500 | 7.54 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.153 | -1.500 | 7.45 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -16.44 | 1.000 | -7.20 | -7.20 | [3 - 30] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -3.97 | -7.95 | [0 - 20] |
debtEquityRatioTTM | 0.202 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.980 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.219 | 1.000 | 7.63 | 7.63 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.40 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.925 | 0.800 | 7.17 | 5.73 | [0.5 - 2] |
Total Score | 5.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.980 | 1.000 | -0.00198 | 0 | [1 - 100] |
returnOnEquityTTM | 0.416 | 2.50 | 7.74 | 9.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -7.95 | [0 - 30] |
dividendYielPercentageTTM | 57.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.729 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.560 |
MEI Pharma Inc
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。